INTRODUCTION
Despite the recent increase in pharmacologic data suggesting that prostaglandins have a broad spectrum of actions, it has been difficult to document that these 20 carbon fatty acids possess important physiologic activities. The limiting problem has been the lack of suitable methods for measuring concentrations of endogenous prostaglandins. Spectrophotometric measurements (1) (2) (3) are relatively specific and simple, but are sensitive only in the low microgram range. Techniques which combine gas chromatography and mass spectroscopy (4, 5) are specific and are very useful in the measurement of products of prostaglandin degradation;' the sensitivity of these methods, however, is limited to the high picogram range and time requirements make them inapproReceived for publication 1 August 1972 and in revised form 13 October 1972. priate for measurement of large numbers of samples.
Bioassay systems have been utilized in the past (6) (7) (8) (9) (10) (11) , but they have serious limitations in sensitivity and specificity and obviously depend on biological responses.
We have previously described a radioimmunoassay capable of measuring subpicomole amounts of prostaglandins (12, 13) . Despite the availability of these antibodies, there were two major difficulties which had to be solved before the immunoassay could, be applied to the measurement of prostaglandins in tissue and plasma: (a) in equilibrium dialysis, an average of 30% of prostaglandin El (PGE1) 1 0.1 to 100 ng/ml is bound to human serum albumin (HSA), 10 mg/ml; this extensive binding of prostaglandins to albumin and other proteins diminishes immunoassay sensitivity, and (b) the significant degree of immunological cross-reactivity among the various prostaglandins and their antisera make quantitation of the individual prostaglandins difficult. This report is concerned with the solution of these problems. Protein binding has been eliminated by utilizing an organic solvent extraction procedure that separates prostaglandins from plasma proteins. Problems related to immunological cross-reactivity have been circumvented by chromatographic separation of prostaglandins into three major groups, PGE, PGA, and PGF (14) (15) (16) p.m., unless otherwise specified, were collected in plastic syringes, kept at 4°C, and centrifuged within 1 h after collection to separate the plasma. 1 ml plasma samples were placed in conical glass graduated centrifuge tubes and 13 pg (4,000 cpm) of ['H]PGE1 (New England Nuclear
Corp., Boston, Mass., 87 C/mM) in 0.05 ml were added.
The plasma was extracted with 3.0 ml of petroleum ether to remove neutral lipids. The aqueous layer was then exposed to 3.0 ml of 3: 3: 1 ethyl acetate: isopropanol: 0.1 M HCl, apparent pH 5.8, and vortexed, and a mixture of 2.0 ml of ethyl acetate and 3.0 ml of water was added. After further mixing, the two phases were separated by centrifugation (2,000 rpm for 5 min at ambient temperatures). 3 ml of the 3.5 ml organic phase were removed by aspiration and dried in air at 550C.
Chromatographic separation of prostaglandins. Silicic acid slurry (Sigma Chemical Co., St. Louis, Mo., 100 mesh) was made up to 0.25 g/ml in 60: 40 benzene: ethyl acetate (solvent 1). After adding 2.0 ml of slurry to each column (10 ml disposable pipettes with glass wool inserted at their tips), the resin was washed with 5.0 ml of solvent 2 (benzene: ethyl acetate: methanol, 60: 40: 20) and 1.5 ml of solvent 1. Sample residues were vortexed in 0.2 ml of solvent 3 (benzene: ethyl acetate: methanol, 60: 40: 10) and then 0.8 ml of solvent 1. The combined organic extracts were applied to the columns which were allowed to run dry. Prostaglandin fractions were obtained by developing the columns serially with 6 ml of solvent 1 (fraction I, PGA and PGB), 12 ml of solvent 4 (benzene: ethyl acetate: methanol 60: 40: 2) (fraction II, PGE), and 3 ml of solvent 2 (fraction III, PGF). The fractions were taken to dryness by evaporation in air at 550C and dissolved in 1.0 ml of 0.15 M NaCl-0.01 M phosphate pH 7.54 containing gelatin (Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y.) 1 mg/ml, gelatin phosphate buffered saline (GPBS). Samples of the aqueous fractions were dissolved in 0. Antiprostaglandin antibodies. Antibodies to PGE,, PGA1, and PGF2o! were elicited by immunizing animals to prostaglandin-protein conjugates. The details of immunogen preparation and characterization, and the schedule of immunizing injections have been previously described (12, 13, 16 Radioimmunoassay system. For each assay (i.e., PGE, PGA, and PGF), 0.05 ml each of appropriately diluted antibody in GPBS, 8,000-10,000 cpm of tritiated prostaglandin (New England Nuclear Corp., PGE1, 87 C/mM, PGA,, 81 C/mM, or PGF,,a, 73 C/mM), and 1 mM EDTA are incubated for 1 h at 4VC with either unlabeled prostaglandins (15- 4,000 pg) or the unknown sample as a silicic acid fraction in 0.1 ml of GPBS. Before separation of antibody-bound from unbound ['H] PG, 0.1 ml of phosphate-buffered saline (PBS) containing 5 mg/ml gelatin is added to prevent nonspecific binding and stabilize the separation procedure (if added earlier, gelatinization prevents adequate reaction). Separation is accomplished by adding to the reaction vials 1.0 ml of dextran-coated charcoal (activated Norit A, 2.5 mg/ml: dextran T70, Pharmacia Fine Chemicals Inc., Piscataway, N. J. 0.25 mg/ml in PBS) (15) (16) (17) . After a 10 min centrifugation at 40C, 3 Antiprostaglandin antibodies. The cross-reactivity of antibodies to PGA1 has been described previously (12, 13 The specificity of the anti-PGF2a antibodies has been described in detail (16) . Although PGF1a has a relative cross-reactivity of 0.453 (2.2 times the amount of PGF1. is required to displace the same amount of marker as PGF2. ), the corresponding values for PGE and PGA derivatives are less than 0.001. At the dilution used, 1: 6,000, anti-F antibodies bind 40% of [3H]
PGF1a.
The major immediate plasma metabolites of prostaglandins are 15-keto derivatives (19) , which crossreact to a negligible degree with antiprostaglandin antibodies (P < 0.004). Since these compounds circulate in concentration approximately 30 times that of the native compounds, (20) they do not appear to interfere with the radioimmunoassay system. Similarly, arachidonic acid, at the reported serum concentration, 7 /ig/ml (21), does not interfere with the PGE radioimmunoassay.
Only 2-3% of [3H]arachidonic acid is recovered in any PG fraction. In addition, relative cross-reactivity of arachidonic acid with anti-PG antibodies is less than 0.00001. The combination of the extraction procedure and the very low degree of antibody cross-reactivity also excludes interference by linoleic and other free unsaturated fatty acids, steroid hormones, fat-soluble vitamins, and compounds that interact with the adenyl cyclase system.
We have found good agreement in data comparing PGE concentrations as measured by radioimmunoassay and by two bioassays, the cat blood pressure bioassay (11) and the organ superfusion bioassay technique (8) . These observations further substantiate the ability of the radioimmunoassay to measure active prostaglandins.
Measurement of plasma prostaglandin concentrations. . Table I. respectively; for the second patient, C. J., data were 830, 1,065, 1,071, 470 pg/ml, respectively. Thus, for these two patients, PGE levels varied considerably during the day but were higher in the morning than in the late afternoon.
Peripheral plasma concentrations of prostaglandins might be expected to be high in patients with medullary carcinoma of the thyroid (22) and associated malignancies (23, 24) . Concentrations of PGE in the plasma of patients with these malignancies are listed in Table  II . Neither patient with medullary carcinoma of the thyroid had associated diarrhea but both had widespread metastatic carcinoma and in addition, had elevated levels of thyrocalcitonin in their sera (25) . The first patient with a carcinoid tumor (patient M. J.) had a primary lesion in the jejunum and carcinoid syndrome manifested primarily by flushing and accompanied by mild elevation of urinary 5-hydroxy indole acetic acid; the second patient in this group (W. C.) had an enormous carcinoid tumor of the rectum with extensive hepatic involvement but no symptoms of carcinoid syndrome. The last patient (N. J.) was an infant girl who died of a neuroblastoma and was very symptomatic with profound diarrhea. In patients 1, 3, and 5, concentrations of PGE were elevated above the range of any of the 40 normal subjects studied; levels in patients 2 and 4 were at the upper limits of "normal." One patient with a pheochromocytoma had normal PGE levels both before and after resection of the tumor.
One way of validating the specificity of the prostaglandin measurements is to study the effect of inhibitors of PGE synthesis on serum and tissue PGE concentrations. Under urethane anesthesia, the left kidneys of 10 control and 10 indomethacin treated rats were clamped for 41 h; 5 min after release of the clamps, the rats were exsanguinated. Renal (right and left) and serum concentrations of PGE were measured. Indomethacin, a potent inhibitor of prostaglandin synthesis (26) (27) (28) , lowered PGE concentrations in rat serum and kidney 67.0 and more than 98% (Table III) (30, 31, 36) . We have previously shown that by taking precautions to to avoid prostaglandin degradation and by immunization of multiple animals, it is possible to obtain anti-E and anti-A antibodies with considerable group specificity (12, 13) . Each of the antibodies demonstrates specificity for both the cyclopentane ring (and hence distinguish between PGE, PGA, and PGF compounds) as well as the aliphatic side chains (and hence can distinguish between PGA1 and PGA2, etc.). Using the homologous antiserum and marker, as little as 5 pg of PGA and PGE can be measured. Despite the relative specificity of the antisera we believe it is highly desirable to eliminate possible uncertainty by including an extraction-chromotographic separation procedure in the preparation of samples for measurement. The method for prostaglandin extraction and chromatographic separation described in this paper results in good recovery, is reproducible, can be easily applied to the measurement of tissue prostaglandin concentrations, and does not convert significant amounts of PGE to PGA. The extraction procedure should also eliminate possible difficulties from enzymes in plasma capable of degrading prostaglandins. In serum incubated at 370C, a slow conversion of PGA and PGB takes place, apparently due to the presence of prostaglandin A isomerase (40) . After removal of the proteins present in serum by extraction, this conversion should no longer be possible.
While the combined immunoassay-chromatographic separation procedure eliminates any problems created The major pathway of PGE and PGF metabolism is enzymatic conversion of the hydroxyl group at the 15 position to a largely inactive keto derivative (19, (41) (42) (43) predominantly in the lung (44) (45) (46) . The existing data indicates that this degradation occurs very rapidly with conversion of the majority of PGE in one passage through the lungs. Most of the enzymatically inactivated prostaglandin is returned to the plasma for further metabolism or excretion. Since 15-keto prostaglandins are likely to circulate in significant concentrations, the fact that 15-keto prostaglandin derivatives do not cross-react immunologically to any significant degree is essential to the accuracy of PGE and PGF measurements. Similar enzymatic oxidation does not appear to occur with PGA compounds (47, 48) and this undoubtedly contributes to their relatively high concentrations in plasma by comparison with those of PGE and PGF. The dependency of blood PGE levels on continuous prostaglandin synthesis and release is further suggested by the results in indomethacin-treated rats where the drug produced a marked depression of serum and kidney PGE concentrations. The diminution of PGE under these circumstances can be explained by the ability of indomethacin to block the conversion of prostaglandin precursors to prostaglandins.
The fall in measurable PGE in association with indomethacin treatment provides important substantiation of the specificity of the assay for prostaglandin.
In contrast to the very low circulating levels of PGE induced by inhibition of the prostaglandin synthesis, it seems highly probable that the very high PGE concentrations in the plasmas of three of five patients with specific malignancies represent active secretion of prostaglandins by the tumors. Prostaglandin release by a variety of cell lines in tissue culture has been described previously from this laboratory (49, 50) . The presence of large amounts of prostaglandins in human medullary carcinoma tissue has been suggested on the basis of bioassay measurements of tumor and serum extracts from patients with this condition (22). Our immunochemical measurements provide direct substantiation for the occurrence of increased circulating prostaglandin concentrations in association with certain tumors.
Elevated levels of circulating PGE have also been noted in two additional situations. In rats made hypertensive by ligating the branches to the lower pole of the left kidney (and not in control rats) concentrations of PGE in the ischemic kidneys were significantly higher than in the contralateral kidneys. (1962±383 vs. 1205+ 282 pg/g). Animals with surgically-induced renal ischemic also had a doubling in serum PGE levels (29) , (1583±298 vs. 737±267 pg/ml). In addition, in studies of 32 human females we have noted elevations of plasma PGE during labor and in cord blood, but normal concentrations both during pregnancy and 24 h after delivery.2 Finally although previous reports suggested that PGE levels in aqueous humor might be elevated in patients with primary open angle glaucoma (51), we have been unable to demonstrate such a difference (52 
